Eusol Biotech Co.,Ltd. (TPEX:6652)
Taiwan
· Delayed Price · Currency is TWD 6.56
+0.21 (3.31%)
Mar 10, 2026, 1:46 PM CST
Eusol Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 0.37 | - | - | - | - | - | Upgrade
|
| Gross Profit | 0.2 | - | - | - | - | - | Upgrade
|
| Selling, General & Admin | 13.21 | 15.03 | 16.72 | 24.38 | 24.89 | 21.66 | Upgrade
|
| Research & Development | 31.54 | 26.08 | 24.76 | 52.38 | 97.88 | 92.59 | Upgrade
|
| Operating Expenses | 44.75 | 41.1 | 41.48 | 76.76 | 122.77 | 114.24 | Upgrade
|
| Operating Income | -44.56 | -41.1 | -41.48 | -76.76 | -122.77 | -114.24 | Upgrade
|
| Interest Expense | -0.05 | -0.08 | -0.14 | -0.22 | -0.22 | -0.14 | Upgrade
|
| Interest & Investment Income | 6.6 | 5.94 | 4.63 | 2.01 | 0.72 | 0.54 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.46 | 1.65 | -0.37 | 0.01 | -0.2 | -0.56 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.36 | 0.4 | 0.49 | 0.74 | -1.12 | 0.79 | Upgrade
|
| EBT Excluding Unusual Items | -39.1 | -33.19 | -36.87 | -74.23 | -123.58 | -113.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -12.45 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.32 | 0.28 | 0.2 | 113.58 | - | 0.12 | Upgrade
|
| Asset Writedown | - | - | - | -51.58 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.06 | - | - | Upgrade
|
| Pretax Income | -37.78 | -32.92 | -49.12 | -12.29 | -123.58 | -113.5 | Upgrade
|
| Income Tax Expense | -0 | -2.37 | 2.49 | 6.02 | -0.27 | 0.27 | Upgrade
|
| Earnings From Continuing Operations | -37.78 | -30.55 | -51.61 | -18.31 | -123.31 | -113.77 | Upgrade
|
| Net Income | -37.78 | -30.55 | -51.61 | -18.31 | -123.31 | -113.77 | Upgrade
|
| Net Income to Common | -37.78 | -30.55 | -51.61 | -18.31 | -123.31 | -113.77 | Upgrade
|
| Shares Outstanding (Basic) | 137 | 137 | 137 | 137 | 134 | 125 | Upgrade
|
| Shares Outstanding (Diluted) | 137 | 137 | 137 | 137 | 134 | 125 | Upgrade
|
| Shares Change (YoY) | - | - | - | 2.21% | 7.23% | - | Upgrade
|
| EPS (Basic) | -0.28 | -0.22 | -0.38 | -0.13 | -0.92 | -0.91 | Upgrade
|
| EPS (Diluted) | -0.28 | -0.22 | -0.38 | -0.13 | -0.92 | -0.91 | Upgrade
|
| Free Cash Flow | -36.14 | -32.99 | -43.1 | -52.88 | -89.45 | -91.59 | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -0.24 | -0.32 | -0.39 | -0.67 | -0.73 | Upgrade
|
| Gross Margin | 52.70% | - | - | - | - | - | Upgrade
|
| Operating Margin | -12041.89% | - | - | - | - | - | Upgrade
|
| Profit Margin | -10210.81% | - | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -9768.65% | - | - | - | - | - | Upgrade
|
| EBITDA | -43.53 | -39.96 | -39.8 | -56.96 | -99.3 | -89.6 | Upgrade
|
| D&A For EBITDA | 1.03 | 1.15 | 1.68 | 19.8 | 23.47 | 24.65 | Upgrade
|
| EBIT | -44.56 | -41.1 | -41.48 | -76.76 | -122.77 | -114.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.